Olalekan Oluwole, MD
Hematology & Oncology · Nashville, TNNPI 1699947655
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $228,627 of the $311,412 with a category attached, or 73.4%. Gilead accounts for 74.2% of it on its own, with 20 other manufacturers making up the rest. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $1605.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$231K
- ADC Therapeutics America, Inc.$39K
- E.r. Squibb & Sons, L.L.C.$11K
- Pfizer$8K
- Johnson & Johnson$6K
- Merck$5K
- plus $13K from 15 others
Across 420 payments — averaging $12,904 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$4.9M
- Daiichi Sankyo Inc.$320K
- GSK$114K
- AbbVie$25K
- E.r. Squibb & Sons, L.L.C.$16K
- Janssen Research & Development, LLC$4K
- plus $4K from 1 others
What the payments were for
- Consulting fees$228,62773%
- Speaking & faculty fees$21,2607%
- Travel & lodging$55,28818%
- Food & beverage$6,1662%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 119 | $231,052 |
| ADC Therapeutics America, Inc. | 37 | $39,052 |
| E.r. Squibb & Sons, L.L.C. | 4 | $10,505 |
| Pfizer | 2 | $7,655 |
| Johnson & Johnson | 6 | $5,555 |
| Merck | 2 | $4,695 |
| Kyowa Kirin, Inc. | 3 | $3,142 |
| Beigene USA, Inc. | 1 | $2,625 |
| TG Therapeutics, Inc. | 1 | $2,025 |
| Epizyme, Inc. | 1 | $1,500 |
| Janssen Global Services, LLC | 2 | $1,180 |
| Novartis | 1 | $983 |
| AbbVie | 2 | $439 |
| Bristol Myers Squibb | 4 | $428 |
| Rigel Pharmaceuticals, Inc. | 1 | $131 |
| AstraZeneca | 2 | $107 |
| Sobi, Inc | 1 | $80 |
| Adaptive Biotechnologies Corporation | 1 | $74 |
| Astellas Pharma US Inc | 1 | $72 |
| Sanofi-aventis U.S. LLC | 1 | $71 |
| Taiho Oncology, Inc. | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$311,412 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 29 | $372,819 |
| BrukinsaZanubrutinib | 22 | $151,033 |
| PromactaEltrombopag Olamine | 17 | $140,083 |
| ValacyclovirValacyclovir Hcl | 90 | $3,161 |
| Fluconazole | 24 | $2,166 |
| Prochlorperazine Maleate | 20 | $895 |
| Entecavir | 17 | $669 |
| Ondansetron Hcl | 25 | $317 |
| Levofloxacin | 18 | $223 |
| Amoxicillin-Clavulanate Pot ErAmoxicillin/Potassium Clav | 11 | $211 |
| Levetiracetam | 19 | $184 |
| Allopurinol | 32 | $117 |
| Omeprazole | 17 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $107 | $372,81929 claims |
| Beigene USA, Inc.Brukinsa | $2,625 | $151,03322 claims |
| NovartisPromacta | $983 | $140,08317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Jack ErterNashville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.